Catalio Capital Management
Latest statistics and disclosures from Catalio Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DNTH, BBIO, ASND, BMY, SNDX, and represent 33.12% of Catalio Capital Management's stock portfolio.
- Added to shares of these 10 stocks: BBIO (+$32M), DFTX (+$20M), INCY (+$17M), RARE (+$14M), TERN (+$14M), CRVS (+$13M), Veradermics (+$11M), KALV (+$8.6M), SLNO (+$7.3M), HTFL (+$7.0M).
- Started 10 new stock positions in BBIO, ATAI, NAMS, IMCR, Veradermics, DFTX, INCY, TYRA, KALV, CRVS.
- Reduced shares in these 10 stocks: BBOT (-$31M), LLY (-$28M), JNJ (-$25M), , GILD (-$18M), , BMY (-$14M), ADMA (-$10M), ACLX (-$10M), SUPN (-$10M).
- Sold out of its positions in ADMA, ACLX, BLLN, BBOT, FULC, GRAL, ISRG, JNJ, LLY, OCUL. OLMA, PVLA, REGN, Atai Life Sciences Nv.
- Catalio Capital Management was a net seller of stock by $-82M.
- Catalio Capital Management has $479M in assets under management (AUM), dropping by -15.39%.
- Central Index Key (CIK): 0001958125
Tip: Access up to 7 years of quarterly data
Positions held by Catalio Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Catalio Capital Management
Catalio Capital Management holds 41 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Dianthus Therapeutics (DNTH) | 9.8 | $47M | -14% | 560k | 83.92 |
|
| Bridgebio Pharma (BBIO) | 6.7 | $32M | NEW | 432k | 74.26 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 6.2 | $30M | +8% | 129k | 228.73 |
|
| Bristol Myers Squibb (BMY) | 5.3 | $26M | -35% | 421k | 60.65 |
|
| Syndax Pharmaceuticals (SNDX) | 5.1 | $24M | -12% | 1.0M | 23.36 |
|
| Gilead Sciences (GILD) | 4.8 | $23M | -43% | 164k | 139.37 |
|
| Terns Pharmaceuticals (TERN) | 4.5 | $22M | +198% | 409k | 52.72 |
|
| Definium Therapeutics Com Shs (DFTX) | 4.1 | $20M | NEW | 1.0M | 18.90 |
|
| Soleno Therapeutics (SLNO) | 4.0 | $19M | +60% | 578k | 33.48 |
|
| Boston Scientific Corporation (BSX) | 3.9 | $19M | -16% | 299k | 62.75 |
|
| Ultragenyx Pharmaceutical (RARE) | 3.7 | $18M | +423% | 851k | 20.95 |
|
| Incyte Corporation (INCY) | 3.6 | $17M | NEW | 182k | 94.12 |
|
| Cytokinetics Com New (CYTK) | 3.0 | $14M | -16% | 216k | 65.91 |
|
| Natera (NTRA) | 3.0 | $14M | +13% | 71k | 199.99 |
|
| Corvus Pharmaceuticals (CRVS) | 2.7 | $13M | NEW | 892k | 14.63 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 2.6 | $12M | 255k | 48.20 |
|
|
| Mineralys Therapeutics (MLYS) | 2.5 | $12M | +32% | 439k | 27.09 |
|
| Edwards Lifesciences (EW) | 2.4 | $12M | -22% | 145k | 80.08 |
|
| Veradermics Common Stock | 2.3 | $11M | NEW | 174k | 63.15 |
|
| Adaptive Biotechnologies Cor (ADPT) | 2.1 | $10M | -11% | 723k | 13.88 |
|
| Heartflow Inc/Sh (HTFL) | 2.1 | $9.8M | +254% | 404k | 24.33 |
|
| Kalvista Pharmaceuticals (KALV) | 1.8 | $8.6M | NEW | 427k | 20.13 |
|
| Uniqure Nv SHS (QURE) | 1.7 | $8.0M | +70% | 491k | 16.35 |
|
| Disc Medicine (IRON) | 1.6 | $7.9M | +11% | 123k | 63.94 |
|
| Septerna (SEPN) | 1.5 | $7.1M | 294k | 24.03 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 1.1 | $5.3M | -52% | 47k | 111.35 |
|
| Dyne Therapeutics (DYN) | 1.1 | $5.1M | -45% | 283k | 18.13 |
|
| Eledon Pharmaceuticals (ELDN) | 1.1 | $5.1M | +30% | 1.6M | 3.08 |
|
| Karyopharm Therapeutics Com New (KPTI) | 1.0 | $5.0M | +527% | 898k | 5.57 |
|
| Supernus Pharmaceuticals (SUPN) | 0.7 | $3.2M | -75% | 62k | 51.69 |
|
| Protara Therapeutics Com Stk (TARA) | 0.6 | $3.0M | -59% | 580k | 5.21 |
|
| Phathom Pharmaceuticals (PHAT) | 0.6 | $2.8M | -64% | 248k | 11.11 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.6 | $2.7M | NEW | 84k | 32.01 |
|
| Tyra Biosciences (TYRA) | 0.5 | $2.6M | NEW | 67k | 38.30 |
|
| Immunocore Hldgs Ads (IMCR) | 0.5 | $2.5M | NEW | 84k | 30.15 |
|
| Fractyl Health (GUTS) | 0.5 | $2.5M | 5.5M | 0.46 |
|
|
| Hyperfine Com Cl A (HYPR) | 0.3 | $1.4M | 1.3M | 1.08 |
|
|
| Metagenomi (MGX) | 0.1 | $709k | 529k | 1.34 |
|
|
| Ataibeckley Com Shs (ATAI) | 0.1 | $697k | NEW | 197k | 3.54 |
|
| Sensei Biotherapeutics Com New (SNSE) | 0.1 | $464k | 15k | 31.52 |
|
|
| Outset Med Com New (OM) | 0.1 | $454k | 118k | 3.84 |
|
Past Filings by Catalio Capital Management
SEC 13F filings are viewable for Catalio Capital Management going back to 2025
- Catalio Capital Management 2026 Q1 filed May 15, 2026
- Catalio Capital Management 2025 Q4 filed Feb. 17, 2026
- Catalio Capital Management 2025 Q3 filed Nov. 14, 2025